Spectrum of HIV lymphoma 2009.
OBJECTIVE
HIV-infected individuals remain at an increased risk for developing malignancies despite the use of combined antiretroviral therapy. Lymphomas comprise a large proportion of the malignancies that affect the HIV-infected population in developed countries. This review summarizes the recent progress made in HIV lymphoma research published in 2009 through January 2010.


RESULTS
The majority of investigation in this field has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising. Rituximab likely improves complete response and possibly overall survival, but may be associated with increased infections in a subset of patients with very low CD4 cell counts. Risk factors associated with the development of lymphoma include low CD4 cell count and likely cumulative HIV viremia. Biologic insights have been realized regarding pathogenesis.


CONCLUSIONS
Overall, the outcome for HIV lymphoma continues to improve as insights into the pathophysiology and treatment advance.
Gucalp
Ayca
A
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Noy
Ariela
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D003131:Combined Modality Therapy; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000150:complications / Q000628:therapy*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000150:complications / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000628:therapy; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000379:methods*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab